Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry

Herz

Volumn 37, Issue 3, 2012, Pages 294-300

  Gitt, A K ^a,b   Bramlage, P ^c   Binz, C ^d   Krekler, M ^d   Deeg, E ^b   Tschope D ^e,f  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b Institut fur Herzinfarktforschung Ludwigshafen   (Germany)

^c Institut fur Pharmakologie und Praventive Medizin   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Deutschen Diabetes Stiftung   (Germany)

Author keywords

Antidiabetic pharmacotherapy; Diabetes; Heart failure; Hypoglycaemia; Treatment outcome

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLINDNESS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HEART FAILURE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863101230     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3611-3     Document Type: Article

References (21)

1. Garcia MJ, McNamara PM, Gordon T et al (1974) Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23: 105-111
2. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34
3. Leung AA, Eurich DT, Lamb DA et al (2009) Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail 15: 152-157
4. Zhou L, Deng W, Fang P et al (2009) Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev 5: 171-84
5. Varela-Roman A, Grigorian Shamagian L, Barge Caballero E et al (2005) Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study. Eur J Heart Fail 7: 859-864 (Pubitemid 41125906)
6. Gustafsson I, Brendorp B, Seibaek M et al (2004) Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43: 771-777 (Pubitemid 38296474)
7. Hunt SA, Baker DW, Chin MH et al (2001) ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the american college of cardiology/american heart association task force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the international society for heart and lung transplantation; endorsed by the heart failure society of America. Circulation 104: 2996-3007 (Pubitemid 33139116)
8. Bramlage P, Binz C, Krekler M et al (2010) Diabetes Treatment Patterns and Goal Achievement in primary diabetes care (DiaRegis). Cardiovasc Diabetol 9: 54
9. Gitt AK, Bramlage P, Binz C et al (2011) Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry. Eur J Cardiovasc Prev Rehabil [in print]
10. Tschope D, Bramlage P, Binz C et al (2011) Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients-an analysis of the DiaRegis registry. Cardiovasc Diabetol 10: 66
11. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412 (Pubitemid 30609442)
12. Dungan KM, Binkley P, Nagaraja HN et al (2011) The effect of glycaemic control and glycaemic variability on mortality in patients hospitalized with congestive heart failure. Diabetes Metab Res Rev 27: 85-93
13. Merck (2007) Summary of Product Characteristics Glucophage
14. Eurich DT, McAlister FA, Blackburn DF et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335: 497
15. Aguilar D, Chan W, Bozkurt B et al (2011) Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4: 53-58
16. (o A) (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853
17. Roussel R, Travert F, Pasquet B et al (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170: 1892-1899
18. Eurich DT, Majumdar SR, McAlister FA et al (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28: 2345-2351 (Pubitemid 41384275)
19. Masoudi FA, Inzucchi SE, Wang Y et al (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111: 583-590 (Pubitemid 40216485)
20. Dargie HJ, Hildebrandt PR, Riegger GA et al (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49: 1696-704 (Pubitemid 46589926)
21. Giles TD, Miller AB, Elkayam U et al (2008) Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 14: 445-452 (Pubitemid 352040859)